Informa Life Sciences is part of the Knowledge and Networking Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.
Managing Director, Commercial Practice Lead at Latham BioPharm Group, Inc., PMP
Dr. Joshua Speidel has eight years of experience managing pre-discovery programs to the lifecycle management of mature products post-licensure. With Latham BioPharm Group (LBG), Dr. Speidel has led teams in the submission of proposals resulting in >$89M of awards. Dr. Speidel provides federal contract compliance services and technical expertise to clients and contributes to the operational management of LBG. As a Health Scientist for the U.S. Department of Health and Human Services (HHS), Biomedical Research and Development Authority (BARDA), he assisted and led teams responsible for the established core capabilities to support the licensure of medical countermeasures in the areas of manufacturing capacity, product development, clinical studies, and long-term stockpiling. While consulting to the U.S. Defense Advanced Research Projects Agency (DARPA), Dr. Speidel created programmatic concepts that were pitched to DARPA’s director and resulted in excess of $250M in contract awards, was the technical point of contact for two teams in the “Accelerated Manufacturing of Pharmaceuticals” program which pioneered efforts in recombinant vaccine production, and was the project manager for their $100M response to the H1N1 pandemic, advancing a pre-discovery stage vaccine candidate through a Phase 1 Clinical Trial, on time and on budget. Dr. Speidel received a Ph.D. in Physiology and Biophysics from Cornell University, a M.Sc. in Biochemistry and Biophysics from the University of Houston and a B.S. in Biochemistry and Molecular Biology from Pennsylvania State University.